Executive Vice President, International Markets Commercial · TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Mark Sabag

A named executive officer of TEVA PHARMACEUTICAL INDUSTRIES in every fiscal year CompBrief holds from FY2017 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$3,729,134

Salary $688,147Stock awards $1,999,990

FY2022: $3,923,933

5th of 5 named executive officers at Teva Pharmaceutical Industries by FY2023 total.

5 named officers on file for TEVA PHARMACEUTICAL INDUSTRIES, FY2023

Mark Sabag’s pay file — $29

  • 5 fiscal years of pay, line by line
  • 6 equity grants, each cited to its filing
  • TEVA’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how TEVA PHARMACEUTICAL INDUSTRIES’s whole pay program stands against its peers

  • TEVA PHARMACEUTICAL INDUSTRIES’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on TEVA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 16, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Mark Sabag’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Mark Sabag compensation by year

TEVA PHARMACEUTICAL INDUSTRIES Summary Compensation Table · all 5 fiscal years held
In US dollars, as TEVA PHARMACEUTICAL INDUSTRIES reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018FY2021FY2022FY2023
Salary$604,637$605,749$765,294$744,787$688,147
Bonus$0$0$0$0$0
Stock awards$1,066,630$2,254,711$1,999,991$1,999,995$1,999,990
Option awards$533,375$866,685$0$0$0
Non-equity incentive$0$1,090,467$732,686$899,554$774,323
Pension and deferred compensation$0$0$0$0$0
All other$317,108$427,724$290,770$279,597$266,674
Total$2,521,750$5,245,336$3,788,741$3,923,933$3,729,134

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: TEVA PHARMACEUTICAL INDUSTRIES LTD DEF 14A filed April 16, 2024, accession 0001193125-24-097745, and prior-year filings.

How this page was built: the TEVA PHARMACEUTICAL INDUSTRIES LTD filed document, accession 0001193125-24-097745. Every figure is read from that document and cited to the page and table it appears in. Filed April 16, 2024.

$2.5M
$5.2M
$3.8M
$3.9M
$3.7M
FY17
FY18
FY21
FY22
FY23
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
PSU148,942$1,554,954—
RSU100,536$1,049,596—
RSU99,601$1,039,834—
PSU69,168$722,109—
PSU58,133$606,909—
RSU47,529$496,203—
RSU20,599$215,054—

Per the Outstanding Equity Awards at Fiscal Year-End table in TEVA PHARMACEUTICAL INDUSTRIES LTD's FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

38 Form 4 lines since the FY2023 proxy (filed April 16, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-11-12Exercise or conversion—44,710$34.90125,470
2026-11-12Exercise or conversion derivative—44,710$0.000
2026-11-12Sale—44,710$44.1480,760
2026-11-05Exercise or conversion derivative—46,000$0.0044,710
2026-11-05Sale—46,000$41.9380,760
2026-11-05Exercise or conversion—46,000$34.90126,760
2026-05-01Sale—144,180$34.9980,760
2026-03-17Sale—62,102$30.14224,940

The 8 most recent of 38 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

TEVA PHARMACEUTICAL INDUSTRIES’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Richard FrancisPresident and Chief Executive Officer$25,706,880
Richard DaniellExecutive Vice President, European Commercial$5,164,163
Eli KalifExecutive Vice President, Chief Financial Officer$4,943,832
Eric DrapéExecutive Vice President, Global Operations$4,254,080
Mark Sabag · this pageExecutive Vice President, International Markets Commercial$3,729,134

The full TEVA PHARMACEUTICAL INDUSTRIES compensation record

free company brief

This page is one person within TEVA PHARMACEUTICAL INDUSTRIES's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the TEVA PHARMACEUTICAL INDUSTRIES proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are TEVA PHARMACEUTICAL INDUSTRIES's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Mark Sabag's compensation dossier · One-time report. No refunds.